Milestone Scientific Inc. recently announced an exciting development in the medical field with the commercial rollout of its advanced CompuFlo Epidural System at iHeal Pain Center. This groundbreaking system promises to revolutionize how epidural analgesia is administered, enhancing the safety and efficacy of pain management treatments. The decision to introduce the CompuFlo Epidural System at iHeal not only signifies a strategic milestone for Milestone Scientific but also reflects a wider commitment to improving patient outcomes in pain management.
Enhancing the Epidural Procedure with CompuFlo Technology
The CompuFlo Epidural System stands out in the medical community due to its innovative use of computer-controlled technology that precisely identifies the epidural space using real-time pressure sensing. This ensures that clinicians can administer medications effectively and reduces the risks often associated with traditional methods. By offering higher accuracy in targeting the epidural space, the CompuFlo system enhances patient safety and minimizes the risk of complications including the potential for dural puncture.
In recent years, there has been a growing need for improved pain management solutions. The ongoing opioid crisis necessitates the exploration of alternative methodologies for managing pain, particularly in surgical and obstetric contexts. The introduction of the CompuFlo system at the iHeal Pain Center is seen as a pivotal step towards addressing these challenges and optimizing patient care.
A Strategic Partnership with Axial Biologics
Milestone Scientific is also excited to announce a partnership with Axial Biologics, a collaboration that signifies the depth of commitment to advancing pain management technologies. This partnership focuses on a robust pipeline of clinical trials in various states, exploring the application and efficacy of the CompuFlo Epidural System.
The dual focus on executing the commercial rollout while conducting clinical trials allows for comprehensive data collection that can facilitate further enhancements to the system. The findings from these trials will not only bolster Milestone Scientific’s product offerings but will also aid in the continuous refinement of techniques used in epidural procedures. Axial Biologics’ expertise in biologic therapies complements Milestone Scientific’s innovative technology, fostering an environment for breakthrough developments in pain management.
Medicare Price Assignment: A Validation of Value
Moreover, the recent assignment of a Medicare price code for the CompuFlo Epidural System has validated its potential for adoption across healthcare facilities. This breakthrough signals an acknowledgment of the system’s value in improving care quality and patient outcomes while reducing healthcare costs associated with complications from traditional procedures. The Medicare code assignment paves the way for wider acceptance of the CompuFlo Epidural System, encouraging more pain management centers to adopt this advanced technology.
Robust Pipeline of Clinics in Development
As the partnership progresses, Milestone Scientific is developing an impressive pipeline of clinics throughout multiple states that are participating in trials with the CompuFlo Epidural System. This extensive network not only reinforces the credibility of the system but also increases the opportunity for patient access to this cutting-edge technology.
Clinics actively enrolling in trials underscore the urgency and necessity of improved pain management alternatives that address the challenges posed by conventional techniques. The presence of the CompuFlo Epidural System in these establishments will likely enhance training for clinicians, ensuring they are equipped to offer this premium solution.
A New Direction for Pain Management
The rollout of the CompuFlo Epidural System represents a significant turning point in pain management practices. By reducing the likelihood of complications, improving training for clinicians, and providing real-time feedback during procedures, Milestone Scientific is poised to lead the charge towards safer and more effective pain treatment modalities.
The combination of clinical trials, strategic partnerships, and Medicare validation forms a solid foundation for the system’s successful integration into pain management practices across the country. As Milestone Scientific and Axial Biologics work together, the potential for improved patient care and treatment methodologies is boundless.
The deployment of CompuFlo technology fulfills a critical need in today’s healthcare landscape a need for innovation, safety, and efficacy in pain management practices. It is an exciting time for Milestone Scientific and a promising future for both healthcare providers and patients alike.
Comments